<div id="readability-page-1"><div><div><p>Merck has announced a strategic partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop an improved and more affordable version of its Ebola virus vaccine, <i>Ervebo</i> . The $30m program aims to optimise the vaccine's manufacturing and distribution to expand access in low- and middle-income countries. The main goal is to increase vaccine yield and improve its shelf life, which is currently constrained by a complex, costly process ill-suited to large-scale rollouts.</p><p>Led in collaboration with Hilleman Laboratories, the project will also explore differentiated pricing mechanisms for public-sector buyers. Industry partners SK bioscience and IDT Biologika will be responsible for developing the active ingredient and the vaccine's final formulation, respectively. One key improvement under consideration is enabling <i>Ervebo</i> to be stored for several months in a standard refrigerator, a decisive logistical advantage for remote areas where health infrastructure is limited. </p><p>The partnership forms part of a broader international effort to make epidemic vaccines more accessible and sustainable. By targeting production and distribution constraints, Merck and CEPI aim to strengthen outbreak response capacity in regions particularly vulnerable to Ebola flare-ups, while laying the groundwork for a model that can be replicated for other diseases with epidemic potential.</p></div></div></div>

默克

<p>默克與 CEPI 合作，以提高其埃博拉疫苗 Ervebo 在低收入國家的可及性。該項目投資 3000 萬美元，旨在改善生產和分發，提高疫苗產量和保質期。與 Hilleman Laboratories 的合作將考慮為公共部門買家提供差異化定價。主要改進包括使疫苗能夠在標準冰箱中儲存，便於在偏遠地區分發。此次合作是全球努力使流行病疫苗更具可持續性並加強脆弱地區疫情應對的一部分</p>

默克與 CEPI 合作，旨在提高埃博拉疫苗在低收入國家的可及性